OraSure Technologies (NASDAQ:OSUR – Get Free Report) and Beta Bionics (NASDAQ:BBNX – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.
Institutional & Insider Ownership
93.5% of OraSure Technologies shares are owned by institutional investors. 4.7% of OraSure Technologies shares are owned by company insiders. Comparatively, 5.3% of Beta Bionics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for OraSure Technologies and Beta Bionics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OraSure Technologies | 1 | 2 | 0 | 0 | 1.67 |
| Beta Bionics | 1 | 4 | 9 | 0 | 2.57 |
Profitability
This table compares OraSure Technologies and Beta Bionics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OraSure Technologies | -43.70% | -19.09% | -16.26% |
| Beta Bionics | -61.31% | -26.30% | -23.25% |
Valuation and Earnings
This table compares OraSure Technologies and Beta Bionics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OraSure Technologies | $115.02 million | 2.28 | -$68.73 million | ($0.69) | -5.51 |
| Beta Bionics | $100.25 million | 7.82 | -$73.20 million | ($1.65) | -10.56 |
OraSure Technologies has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
OraSure Technologies has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.39, indicating that its stock price is 239% more volatile than the S&P 500.
Summary
OraSure Technologies beats Beta Bionics on 8 of the 14 factors compared between the two stocks.
About OraSure Technologies
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
